['obesity', 'over-weight', 'hypothalamic injury', 'craniopharyngioma']
['zgn-440 sterile diluent', 'zgn-440 for injectable suspension']

        Inclusion Criteria:

          -  Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by
             BMI ≥30 and ≤60 kg/m2

          -  Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
             with resulting injury to the hypothalamus and/or the pituitary

          -  Stable body weight for at least 3 months

          -  Type 2 diabetes mellitus is allowed

        Exclusion Criteria:

          -  Males taking gonadotropin replacement therapy (LH/FSH)

          -  Subjects who are planning any fertility treatment within 6 months of study
             participation

          -  Use of weight loss agents, including herbal medications, in the past 3 months

          -  Current or anticipated chronic use of narcotics or opiates

          -  History of severe psychiatric disorders

          -  Type 1 diabetes mellitus

          -  Metabolic disorders or genetic disorders linked to obesity

          -  History of any bariatric surgery

          -  Participation in any clinical study with an investigational drug or device within the
             3 months prior to enrollment in this study

          -  Blood loss or donation >500 mL within the past 3 months

          -  Females who are pregnant, nursing, intend to become pregnant during the study or any
             males who plan to father/conceive a child within 6 months after completion of study
             participation
      